BG100974A - Vaccines against papillomavirus - Google Patents

Vaccines against papillomavirus

Info

Publication number
BG100974A
BG100974A BG100974A BG10097496A BG100974A BG 100974 A BG100974 A BG 100974A BG 100974 A BG100974 A BG 100974A BG 10097496 A BG10097496 A BG 10097496A BG 100974 A BG100974 A BG 100974A
Authority
BG
Bulgaria
Prior art keywords
vaccines against
proteins
against papillomavirus
papillomavirus
recombinant
Prior art date
Application number
BG100974A
Other languages
Bulgarian (bg)
English (en)
Inventor
Kathrin Jansen
James Cook
Hugh George
Kathryn HOFMANN
Joseph JOYCE
Ernest LEHMAN
Henry Markus
Mark Rosolowsky
Loren Schultz
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG100974A publication Critical patent/BG100974A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG100974A 1994-05-16 1996-11-12 Vaccines against papillomavirus BG100974A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24279494A 1994-05-16 1994-05-16
PCT/US1995/006006 WO1995031532A1 (fr) 1994-05-16 1995-05-15 Vaccins contre le papillomavirus

Publications (1)

Publication Number Publication Date
BG100974A true BG100974A (en) 1998-04-30

Family

ID=22916213

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100974A BG100974A (en) 1994-05-16 1996-11-12 Vaccines against papillomavirus

Country Status (24)

Country Link
EP (1) EP0757717B1 (fr)
JP (1) JP3863559B2 (fr)
CN (1) CN1152935A (fr)
AT (1) ATE328068T1 (fr)
AU (1) AU693203B2 (fr)
BG (1) BG100974A (fr)
BR (1) BR9507657A (fr)
CA (1) CA2189882C (fr)
CZ (1) CZ336696A3 (fr)
DE (1) DE69535018T2 (fr)
DK (1) DK0757717T3 (fr)
ES (1) ES2264126T3 (fr)
FI (1) FI119815B (fr)
HU (1) HUT76354A (fr)
MX (1) MXPA96005662A (fr)
NO (1) NO322133B1 (fr)
NZ (1) NZ285941A (fr)
PL (1) PL183781B1 (fr)
PT (1) PT757717E (fr)
RO (1) RO117541B1 (fr)
RU (1) RU2206608C2 (fr)
SI (1) SI0757717T1 (fr)
SK (1) SK147696A3 (fr)
WO (1) WO1995031532A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
RU2177999C2 (ru) * 1994-09-22 2002-01-10 Мерк Энд Ко., Инк. Экспрессирующий вектор (варианты)
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
EP1105466B1 (fr) 1998-08-14 2006-04-26 Merck & Co., Inc. Procede permettant de purifier des particules virales de type papillomavirus humain
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
ATE413188T1 (de) 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE60327069D1 (de) 2002-04-30 2009-05-20 Oncolytics Biotech Inc Verbesserte reinigungsmethode für viren
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
CN102794109B (zh) 2004-09-30 2015-10-07 拜耳医药保健有限公司 用于集成连续生产生物分子的装置和方法
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
EP2601969B1 (fr) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Formulations de vaccin contre un norovirus
CL2008000249A1 (es) * 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
CA2683977C (fr) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. Une methode de purification de particule de type norovirus comprenant la chromatographie par echange d'ions
JP5540329B2 (ja) * 2007-06-26 2014-07-02 公益財団法人ヒューマンサイエンス振興財団 高リスク群ヒトパピローマウイルスに対する交差性中和抗体を誘導するワクチン抗原
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
WO2009076824A1 (fr) * 2007-11-23 2009-06-25 Shanghai Zerun Biotechnology Co., Ltd. Gènes codant pour la protéine majeure de capside l1 du virus du papillome humain
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
RU2377305C1 (ru) * 2008-11-13 2009-12-27 Всеволод Иванович Киселев Мукозальная вакцина для иммунотерапии заболеваний, обусловленных вирусами папилломы человека, и способ лечения с ее использованием (варианты)
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
CN102234661A (zh) * 2010-04-23 2011-11-09 北京生物制品研究所 人乳头瘤病毒类病毒颗粒的制备方法和外源蛋白表达盒、表达系统
MX373096B (es) 2010-12-02 2020-04-27 Oncolytics Biotech Inc Formulaciones virales líquidas.
CA2819236A1 (fr) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Formulations de virus lyophilisees
RU2445357C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
RU2445358C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
EA201391605A1 (ru) * 2011-04-29 2014-02-28 Онколитикс Байотек Инк. Способы очистки вирусов с использованием гельпроникающей хроматографии
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
CN103890177B (zh) * 2011-12-01 2016-03-09 开普敦大学 Hpv嵌合颗粒
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN107916234A (zh) * 2012-03-28 2018-04-17 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv6 l1蛋白的方法
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104164374B (zh) * 2013-05-17 2019-10-22 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
CN104673760B (zh) * 2013-11-29 2018-01-02 南京赛威信生物医药有限公司 一种原核细胞表达类病毒颗粒的纯化方法
RU2546243C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики папилломавирусной инфекции человека и способ ее получения
RU2546240C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 56
RU2546242C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 18
RU2546241C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 16
WO2016104923A1 (fr) * 2014-12-26 2016-06-30 아이진 주식회사 Procédé de préparation de particules pseudo-virales du papillomavirus humain
CN108472357A (zh) * 2015-09-04 2018-08-31 创赏有限公司 Vlp稳定的疫苗组合物
RU2676160C1 (ru) * 2018-02-14 2018-12-26 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей Hansenula polymorpha - продуцент главного капсидного белка L1 вируса папилломы человека типа 11
RU2681174C1 (ru) * 2018-07-12 2019-03-04 Закрытое акционерное общество научно-производственная компания "Комбиотех" Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина
HUE073111T2 (hu) 2019-07-19 2026-01-28 Sinocelltech Ltd Kiméra papillomavírus L1 fehérje
CN116426396B (zh) * 2023-06-09 2023-09-01 内蒙古工业大学 一株耐硫酸铵酿酒酵母及其筛选方法
DE102024106741B4 (de) * 2024-03-08 2025-10-09 Schott Ag Mikroarrays mit Nitrozellulosebeschichtung und Herstellungsverfahren

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586428B1 (fr) * 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
DE3625257A1 (de) * 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
EP1359156B1 (fr) * 1991-07-19 2007-03-07 University of Queensland Vaccin contre le Papillomavirus Humain (Type 18)
PT647140E (pt) * 1992-06-25 2007-12-27 Univ Georgetown Vacinas de papilomavírus
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product

Also Published As

Publication number Publication date
MXPA96005662A (es) 2004-08-19
SI0757717T1 (sl) 2006-08-31
CN1152935A (zh) 1997-06-25
AU693203B2 (en) 1998-06-25
PT757717E (pt) 2006-09-29
JP3863559B2 (ja) 2006-12-27
NZ285941A (en) 1998-05-27
PL183781B1 (pl) 2002-07-31
CZ336696A3 (en) 1997-07-16
FI119815B (fi) 2009-03-31
HUT76354A (en) 1997-08-28
CA2189882A1 (fr) 1995-11-23
JPH10500847A (ja) 1998-01-27
ATE328068T1 (de) 2006-06-15
PL317234A1 (en) 1997-03-17
CA2189882C (fr) 2005-09-20
BR9507657A (pt) 1997-09-09
NO964862D0 (no) 1996-11-15
FI964592L (fi) 1996-11-15
DK0757717T3 (da) 2006-09-25
EP0757717B1 (fr) 2006-05-31
RO117541B1 (ro) 2002-04-30
EP0757717A1 (fr) 1997-02-12
NO964862L (no) 1997-01-16
ES2264126T3 (es) 2006-12-16
SK147696A3 (en) 1997-08-06
EP0757717A4 (fr) 1998-04-15
AU2549595A (en) 1995-12-05
WO1995031532A1 (fr) 1995-11-23
RU2206608C2 (ru) 2003-06-20
DE69535018T2 (de) 2007-02-15
FI964592A0 (fi) 1996-11-15
DE69535018D1 (de) 2006-07-06
HU9603155D0 (en) 1997-01-28
NO322133B1 (no) 2006-08-21

Similar Documents

Publication Publication Date Title
HU9603155D0 (en) Papillomavirus vaccines
IL130964A0 (en) Practical in vitro sialylation of recombinant glycoproteins
YU24199A (sh) Upotreba glp-1, njegovih analoga i derivata za pripremu leka za regulaciju telesne težine
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
GB9907461D0 (en) Neurite regeneration
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
ID28003A (id) Turunan-turunan adamantana
NL300273I1 (nl) DNA dat humaan papillomavirus type 18 codeert.
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
MY114140A (en) Novel enzymes and prodrugs for use in antibody-directed enzyme prodrug therapy.
FI972030A7 (fi) Puhdistettuja papillomavirusproteiineja
BG101338A (en) Dna encoding human papillomavirus type 6a
AU3711597A (en) A novel galanin receptor
HU9600727D0 (en) Triaryl-ethylene derivatives for use in therapy
BG102937A (en) Zona pelucida proteins as contraceptives
SE9300735L (sv) Startblock
GB9604518D0 (en) Novel compounds
IL124354A0 (en) Hemoregulatory compounds
ES2191785T3 (es) Proteina de accion antitumoral.
MX9707457A (es) Acido desoxirribonucleico sintetico hibrido l1 de hpv6/11 que codifica proteina l1 de virus de papiloma humano tipo 11.